Entheon Biomedical Announces DMT Drug Supply Agreement with Ofichem Group

PT244 – Mark Haberstroh – Mushrooms, Retreat Centers, and Safety

Mydecine Reports First Quarter 2021 Financial Results and Provides Business Update

More than 80% of Americans report one or more symptoms of...

The Impact of Specific Genes on Cannabis Use Disorder

IntelGenx Announces Initial Closing of atai Investment

Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop...

Bright Minds Biosciences Shares to Commence Trading on the OTCQB Venture...

Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug...

PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of...

Load more